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Abstract 
BACKGROUND: The usefulness of β-blockers in heart failure (HF) patients with permanent atrial fibrillation 
(AF) has been questioned.   
METHODS AND RESULTS: We analyzed data from HF patients (958 patients (801 males, 84%, age 
67±11years) with AF enrolled in the MECKI score database. We evaluated prognosis (composite of 
cardiovascular death, urgent heart transplant, or left ventricular assist device) of patients receiving β-
blockers (n=777, 81%) vs. those not treated with β-blockers (n=181, 19%). We also analyzed the role β1-
selectivity and the role of daily β-blocker dose. To account for different HF severity, Kaplan-Meier survival 
curves were normalized for relevant confounding factors and for treatment strategies.  Dose was available 
in 629 patients. Median follow-up was 1312 (577-2304) days in the entire population, 1203 (614-2420) and 
1325 (569-2300) days in patients not receiving and receiving β-blockers. 224 (23%, 54/1000 events/year), 
163 (21%, 79/1000 events/year), and 61 (34%, 49/1000 events/year) events were recorded, respectively. At 
10-year patients treated with β-blockers had a better outcome (HR 0.447, p<0.01) with no effects as 
regards β1selective drugs (53%) vs. β1-β2 blockers (47%). Survival improved in parallel with β-blocker dose 
increase (HR 0.296, 0.496, 0.490 for the high, medium, and low dose vs. no β-blockers, p<0.0001). 
CONCLUSION: HF patients with AF taking a β-blocker have a better outcome (with a survival improvement 
in parallel with daily dose but no differences as regards β1 selectivity) but this does not mean that β-
blockers improve outcomes in these patients as we cannot control for all the potential confounders 
associated with β-blocker use. 
 
Keywords: Cardiopulmonary exercise test; Prognosis; β-blockers, Atrial fibrillation.  
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Introduction 
Permanent atrial fibrillation is frequently associated with heart failure (HF), and particularly with severe HF, 
where it is present in approximately 50% of cases [1-6]. Although atrial fibrillation is associated with, but 
not directly linked to HF prognosis, its presence affects HF treatment [7-9]. Notably, the usefulness of β-
blockers in HF patients with permanent atrial fibrillation has been recently questioned [1, 10-13], although 
β-blockers are among the cornerstones of HF treatment [14, 15]. Whereas several reports confirm the 
efficacy of β-blockers in HF patients with atrial fibrillation as regards left ventricular ejection fraction (LVEF) 
increase, data on survival are inconclusive, with some reports suggesting survival improvement in patients 
receiving β-blockers and others not. Specifically the reports from RCT's showed no benefit and those from 
non-randomized consorts are the only ones that report a better prognosis with β-blockers [10-13, 16]. 
Moreover, the effects of β-blockers on survival in HF patients is dose-dependent, so that the higher the 
dose, the better the survival rate [17-20]. Unfortunately, the β-blocker dose is unknown, at least in most of 
the studies on HF patients with atrial fibrillation, and this generates a further theme of uncertainty. 
Moreover, it should be noted that clinical trials dedicated to understanding the efficacy of β-blockers in 
patients with HF and concomitant atrial fibrillation do not exist, and that the available information only 
derives from observational studies or sub-analyses of trials on HF. To contribute to the knowledge on this 
topic, we analyzed the MECKI (Metabolic Exercise Cardiac Kidney Index) score database, which is a 
multicenter, progressively enrolling, continuously updated research program on HF patients capable to 
perform a cardiopulmonary exercise test [17, 21]. We identified HF patients with permanent atrial 
fibrillation, which are the source of the present analysis, and we compared the survival of those with and 
without β-blockers, and the outcome predictors, also in relation with β-blocker doses.       
 
Methods 
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We retrospectively analyzed the data of HF patients with permanent atrial fibrillation enrolled in the MECKI 
score database. From a total of 6112 patients, 965patients (15.8%) with HF and permanent atrial fibrillation 
were identified. The inclusion/exclusion criteria of the MECKI score database have been previously 
reported [21]. In brief, we enrolled, in 23 Italian dedicated HF centers, all consecutive HF patients in NYHA 
class I-IV, with history of reduced LVEF(<40%), able to perform a cardiopulmonary exercise test. Exclusion 
criteria where major comorbidities that may per se influence exercise performance and/or prognosis.     
The study endpoint was the composite of cardiovascular death, urgent heart transplant, or left ventricular 
assist device (LVAD). In the first step, we evaluated the prognosis of HF patients with atrial fibrillation 
receiving β-blockers at study enrollment vs. those not treated with β-blockers. To account for different HF 
severity, Kaplan-Meyer survival curves were normalized for the relevant confounding factors included in 
the MECKI score as independent prognosticators, specifically oxygen uptake at peak exercise (peak VO2) as 
a % of the predicted value, ventilation/carbon dioxide production (VE/VCO2) relationship slope, plasma Na
+ 
level, hemoglobin, LVEF, and kidney glomerular filtration rate (applying the MDRD formula) [21].  
Moreover, to rule out the differences in treatment strategy, survival curves were normalized for the 
treatments that resulted significantly different between groups, specifically presence of ICD and/or CRT, 
diuretic, digitalis, statin, allopurinol, and mineralcorticoid receptor antagonist. In the second step, we 
analyzed the differences in survival between patients treated with a β1-β2-blocker such as carvedilol and 
patients treated with a β1 selective blocker as bisoprolol, nebivolol or metroprolol. Finally, we also 
evaluated the role of daily β-blocker dose, grouping patients according to carvedilol-equivalent dose (group 
1 ≤ 12.5 mg/day, group 2 >12.5-≤25 mg/day and group 3 > 25 mg/day). The carvedilol-equivalent dose was 
calculated for nebivolol and bisoprolol as dose x 5, and for metoprolol as dose/4 [17, 22]. Again, Kaplan-
Meyer survival curves were normalized for the same confounding factors.  
Follow-up was performed according to the local HF program, and it ended with the last clinical evaluation 
or when the study endpoint was reached [21]. In case of patient death outside of the hospital where they 
were followed, the medical records of the event were analyzed. The study complies with the Declaration of 
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Helsinki, and all patients provided an informed consent at the time of enrollment. The research protocol 
was approved by the Ethical Committee of Centro Cardiologico Monzino, IRCCS (R116/14-CCM-127).  
 
Statistical analysis  
Continuous variables are presented as mean±SD, and differences between groups were compared using 
the t-test for independent samples or ANOVA with Bonferroni post-hoc test, as appropriate. Categorical 
variables are reported as frequency and percentage, and they were compared using the chi-square test. 
The association endpoint (composite of cardiovascular death, urgent cardiac transplant or LVAD 
implantation) was assessed by Cox regression analysis; the results are presented as hazard ratio. Survival 
analysis was evaluated through Kaplan-Meier analysis and compared by Log-Rank test. A p value <0.05 was 
considered statistically significant. All data were collected in an Excel database, and analyses were 
performed using SAS version 9.4 (SAS Institute, Cary, North Carolina). 
 
Results 
Nine hundred sixty-five patients with HF and permanent atrial fibrillation were identified in the MECKI 
score database. Seven patients were excluded from the analysis because they were treated with β-blocker 
molecules not currently indicated for HF therapy. The remaining 958 patients were finally included: 801 
males, (84%), mean age 67±11 years.  
HF etiology was ischemic cardiomyopathy in 39% of cases. Seven hundred seventy-seven patients (81%) 
were treated with β-blockers, while 181 (19 %) were not (figure 1_supplemental material). The median 
follow-up was 1312 (577-2304) days in the entire population: 1203 (614-2420) and 1325 (569-2300) in 
patients not receiving and receiving β-blocker treatment, respectively (p=NS). As regards the study 
endpoint, 224 (23%), 163 (21%), and 61 (34%) events were recorded in the total population and in patients 
receiving and not receiving β-blocker treatment, respectively. Patients’ characteristics are reported in Table 
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1. At 10 years, an event rate of 49/1000 person-years was observed among patients receiving β-blockers, 
vs. 79/1000 person-years among patients not receiving β-blockers (p<0.01 between patients with and 
without β-blocker group).  At a 10-year survival analysis, patients treated with β-blockers had a significantly 
better outcome than patients not receiving β-blockers (HR 0.447, p <0.0001 adjusted for MECKI variables 
and therapy – specifically: diuretics, digitalis, ICD, CRT, statin, allopurinol, and mineralcorticoid receptor 
antagonist) (figure 1).  
Forty-seven percent of patients received carvedilol, 47% bisoprolol, 4% metoprolol, and 2% nebivolol, with 
no significant differences as regards patients’ characteristics and effect on survival according to β-receptor 
selectivity. A tendency toward a lower VE/VCO2 slope (33.7±8.0 vs. 34.9±9.0, p =0.086) was observed in 
carvedilol-treated patients compared to patients treated with β-selective blockers [23, 24].    
The daily β-blocker dose was available in 629 cases (figure 1_supplemental material). Patients’ 
characteristics according to daily dose are reported in table 2. 286, 199, and 144 patients received low, 
medium, and high β-blocker doses, respectively. Patients with higher β-blocker doses were younger, with 
higher BMI and peak VO2 (ml/min), with more ICD and CRT implanted and more optimized HF therapy 
(Table 2).  At 10 years, an event rate of 27, 41, and 45/1000 person-years was observed among patients 
receiving high, medium, and low β-blocker doses, respectively (p<0.001). A 10-year survival analysis 
revealed a progressively better outcome in parallel with daily β-blocker dose increase (HR 0.296, 0.496, 
0.490 for the high, medium, and low dose vs. no β-blockers, p <0.001, p<0.01, and p<0.001, respectively, 
adjusted for MECKI variables and therapy) (figure 2).  
 
Discussion  
This study shows that, in a HF population followed by experienced physicians and health-care providers, 
patients with permanent atrial fibrillation have a better outcome if treated with β-blockers. Moreover, the 
association between β-blockers and survival improvement was in parallel with daily β-blocker dose 
increase. The β1 selectivity vs. non-selectivity for β-receptors did not influence patient survival.  
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However due to the observational nature of the present study we controlled only some but not all the 
myriad of possible confounders. 
Atrial fibrillation is frequently observed in HF patients, and it is present in ~15% of cases in the MECKI score 
database [1, 17, 21]. Notably, atrial fibrillation is usually associated with severe HF, so that it is present in 
approximatively 50% of patients with peak VO2 < 12 ml/min/kg. However, we have previously shown that 
atrial fibrillation is a marker of severe HF but does not directly affect prognosis [7], although it has been 
known for many years that the restoration of sinus rhythm is associated with an improvement of exercise 
performance[25]. Differently from the results of the present study, some reports suggested the lack of a 
survival benefit in chronic HF patients with atrial fibrillation treated with β-blockers, independently of heart 
rate reduction and LVEF improvement [10-13]. These observations were followed by other reports, and 
recent meta-analyses provided confirmative findings [10, 11]. However, opposite results were also 
published by others but only in non-randomized cohort studies [16].  
Our study shows a survival benefit in HF patients with reduced LVEF and permanent atrial fibrillation when 
treated with β-blockers, and a dose-dependent effect. Peculiar characteristics of the study are the 
prolonged follow-up, the clinical and therapeutic stability of patients at recruitment, as well as the 
experience in HF treatment of the recruiting centers and the consequent effort to provide patients with the 
most updated therapy including the highest β-blocker dose. Indeed, in the only recent study suggestive of a 
positive effect of β-blockers on survival in patients with HF and atrial fibrillation [16], up-titration to 
recommended doses was reported, although the actual β-blocker dose was omitted. In our study, patients 
not receiving β-blockers were generally treated less aggressively than those receiving β-blockers, as shown 
by the lower number of ICD, CRT, statins, AT1 blockers, allopurinol, and diuretics (Table 1). Similarly, 
patients treated with a higher β-blocker dose had a higher number of ICD and CRT and the most up-titrated 
therapy (Table 2).  
Patient follow-up was prolonged, so that changes in the therapeutic regimen were possible, including 
introduction or withdrawal of β-blockers as well as their dose up-titration. However, the survival curves for 
ACCEPTED MANUSCRIPT
AC
CE
PT
ED
 M
AN
US
CR
IP
T
 
 
the general β-blocker-treated population and for the dose-grouped patients progressively diverge shortly 
after the beginning of the follow-up (figure 1 and 2).   
β-blocker selectivity was not associated with differences in prognosis, similarly to what has been recently 
reported by us in the general HF population [17]. However, treatment choice was likely casual and 
independent of any sort of physiological matching between patients and β-blocker molecule characteristics. 
Indeed, a proper match of patients and β-blocker molecules has been reported to improve exercise 
performance, and it might be associated with an effect on prognosis[24].  
β-blockers have an established role in the treatment of chronic HF, with a dose-dependent effect [7, 18-20]. 
Accordingly, guidelines recommend a progressive up-titration of β-blockers in HF, and its omission, 
although frequently reported in several registries, is considered as negligence, if not malpractice [14]. 
However, no specific strategy for β-blocker dosing has been suggested for HF patients with permanent 
atrial fibrillation. The MECKI score database includes, as defined by registry entry criteria, patients in stable 
clinical condition and on optimized treatment. Moreover, it was built with patients recruited and followed 
in HF dedicated centers in which β-blocker up-titration to target dose is mandatory. It must be recognized, 
however, that the β-blocker dosing strategy in the MECKI score database was not pre-specified, but it was 
left to each center program [21]. Accordingly, we do not know whether the β-blocker dose was the real 
maximal dose tolerated by the patients. In MECKI score patients, a high daily β-blocker dose is associated 
with a better outcome both in the general HF population and in HF patients with coexisting atrial fibrillation 
[17]. Consequently, our observation, differently from other reports, speaks in favor of β-blocker dose up-
titration in HF patients with permanent atrial fibrillation.   
When evaluating the prognosis of HF patients, several confounding factors must be taken into account. 
Indeed, peak VO2, ventilation efficiency during exercise as assessed by the VE/VCO2 slope, hemoglobin, 
plasma Na+, LVEF, and glomerular filtration rate as assessed by MDRD formula are among the strongest HF 
predictors, and they are used in combination to predict survival in the MECKI score [21, 26]. In the original 
MECKI score assessment, pharmacological and non-pharmacological treatment did not add to prognosis on 
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top of the MECKI score algorithm [21]. Regardless, treatments that resulted significantly different between 
patients treated or not treated with β-blockers or with different doses were considered as confounding 
factors and included in this analysis.    
This study has several limitations that should be acknowledged. First of all, it is an observational study, so 
that patients were not randomized to β-blocker treatment, type, and dose. Moreover we do not know, due 
to the observational nature of the present study, why patients did not get β-blockers or whether β-blockers 
were tried and found intolerable. Similarly we have no data about patients’ compliance to treatment. 
Secondly, BNP or NT-proBNP were not regularly measured at patient enrollment. Indeed, BNP/NTproBNP 
would have helped the assessment of HF severity. Thirdly, MECKI score inclusion criteria include the 
capability and willingness to perform a maximal cardiopulmonary exercise test. This is a relevant study bias, 
because the most severe HF patients as well as patients unwilling to actively participate in a study were 
excluded. The latter patients are likely those less adherent to therapy and to follow-up criteria [27]. 
Fourthly, we analyzed patients with HF and reduced LVEF, so that our findings cannot be extended to 
patients with preserved or mid-range LVEF, in whom β-blocker therapy has been shown to be potentially 
beneficial [28], or to patients with comorbidities that implied exclusion from the MECKI score database, 
such as severe COPD, moderate-to-severe aortic and mitral stenosis, congenital heart diseases, recent 
myocardial infarction, exercise-induced angina or severe arrhythmias, or presence of any clinical 
comorbidity interfering with exercise performance. Consequently, the MECKI score population is not closely 
representative of a general HF population. Fifthly, heart rate was similar between groups, with and without 
β-blockers. However, heart rate was measured during the resting phase of CPET with respiratory gas 
recording, and therefore our measurements cannot be compared with those recorded in subjects resting in 
supine position. Furthermore, the prognostic role of β-blocker-induced heart rate reduction was not 
considered in our analysis. Indeed, it has been previously reported that heart rate reduction, and not dose, 
is the driving mechanism of the β-blocker-mediated clinical and survival improvement [29]. Our study only 
analyzed β-blocker types and doses. Sixthly, the evaluation of patients including therapy was only done 
once at study run-in. In other words, we did not evaluate any possible therapeutic upgrade during the 
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follow-up, as ICD/CRT or introduction/withdrawal of β-blockers.  Finally, it is unknown whether the positive 
results observed in this study could be applied and extended to all HF populations and centers; this study 
was conducted in patients recruited and followed in HF-dedicated centers, used to therapy optimization 
and to β-blocker up-titration to target dose. 
In conclusion, albeit with a retrospective analysis, in which we controlled some but not all the possible 
confounders we provide strong evidence that, in HF patients with reduced LVEF and permanent atrial 
fibrillation, β-blockers are associated with a better survival, with a dose-dependent effect. β1 selectivity 
does not per se add survival benefits. However to definitively assess this issue a placebo/controlled double 
blind trial is needed. 
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Figure legend 
 
Figure 1: Kaplan-Meier analysis of study endpoint (cardiovascular death, urgent heart transplant or LVAD 
implantation) according to β-blocker treatment at a 10-year follow-up (p=0.002). Red line= β-blocker, blue 
line= no β-blocker.  
 
Figure 2: Kaplan-Meier analysis of study endpoint (cardiovascular death, urgent heart transplant or LVAD 
implantation) according to β-blocker equivalent dose at a 10-year follow-up (p<0.0001). 
Blue line= no β-blocker, red line= low dose (≤ 12.5 mg/day), yellow line= medium dose (>12.5-≤25 mg/day), 
green line= high dose (> 25 mg/day). 
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Table 1. Characteristics of patients with atrial fibrillation not treated and treated with β-blockers 
  β-blockers - (n=181) β-blockers + (n=777) p 
Gender (males n,%) 141 (78%) 660 (85%) 0.02 
Age (years) 68.7±10.4 66.4±11.5 0.015 
BMI (kg/m2) 25.9±3.8 27.1±4.3 0.001 
LVEF (%) 34.6±11.7 33.7±10.8 ns 
SBP (mmHg) 119±17 116±17 ns 
HR at rest (bpm) 77±17 75±15 ns 
Peak VO2 (ml/min) 973±346 1026±370 0.078 
Peak VO2 (ml/min/kg) 13.0±3.9 13.0±4.1 ns 
Peak VO2 (% of predicted) 52.1±16.4 51.6±16.0 ns 
VE/VCO2 slope 35.4±8.3 34.5±8.5 ns 
eGFR (ml/min/1.73m2) 64.9±23.1 66.0±22.7 ns 
Hb (g/dl) 13.3±1.8 13.4±1.7 ns 
NYHA (n,%)    
I 10 (5.5%) 55 (7.1%) ns 
II 89 (49.2%) 427 (55.0%)  
III 80 (44.2%) 283 (34.42%)  
IV 2 (1.1%) 12 (1.5%)  
HF Etiology (n,%)   ns 
Idiopathic 58 (33%) 328 (42%)  
Ischemic 74 (42%) 296 (38%)  
Valvular 18 (10%) 65 (8%)  
Other 28 (16%) 86 (11%)  
ICD (n,%) 26 (14%) 240 (31%) <0.001 
CRT (n,%) 11 (6%) 113 (15%) 0.002 
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ACE-inhibitors (n,%) 127 (70.2%) 535 (68.9%) ns 
ARBs (n,%) 21 (11.6%) 172 (22.1%) 0.002 
Diuretics (n,%) 153 (84.5%) 702 (90.4%) 0.022 
Statins (n,%) 36 (20.1%) 300 (38.8%) <0.001 
Allopurinol (n,%) 39 (21.8%) 247 (31.9%) 0.008 
MRAs (n,%) 86 (47.5%) 476 (61.3%) <0.001 
Antiplatelets (n,%) 48 (26.5) 206 (26.5%) ns 
Oral anticoagulants (n,%) 140 (77.4%) 610 (78.5%) ns 
Digitalis (n,%) 86 (47.5%) 311 (40.0%) 0.07 
Amiodarone (n,%) 61 (33.7%) 208 (26.8) 0.061 
 
BMI= body mass index; LVEF= Left ventricular ejection fraction; SBP= systolic blood pressure; HR= heart 
rate; Peak VO2= oxygen uptake at peak exercise; VE/VCO2 slope= minute ventilation/carbon dioxide 
production relationship (VE/VCO2) slope; eGFR= Estimated Glomerular Filtration Rate by Modification of 
Diet in Renal Disease; Hb= hemoglobin; NYHA= New York Heart Association; HF= heart failure ICD= 
implantable cardioverter defibrillator; CRT= cardiac resynchronization therapy; ACE= angiotensin 
converting enzyme; ARB= angiotensin II receptor blockers; MRAs= mineralcorticoid receptor antagonists. 
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Table 2. Characteristics of patients with atrial fibrillation according to β-blocker dose 
  β-blockers - 
(n=181) 
Low dose 
(n=286) 
Medium 
dose (n199) 
High dose 
(n=144) 
ANOVA 
Gender (males n,%) 141 (78%) 242 (85%) 168 (84%) 125 (87%) ns 
Age (years) 68.7±10.4* 68±10.6* 67±11.1* 61.3±13.1 <0.001 
BMI (kg/m2) 25.9±3.8* 26.9±4.4 27.4±4.5° 27.7±4.3 <0.001 
LVEF (%) 34.6±11.7 34.3±10.8 34.0±10.5 33.2±10.1 ns 
SBP (mmHg) 119±17 116±18 116±17 116±17 ns 
HR at rest (bpm) 77±17 76±15 75±13 77±17 ns 
Peak VO2 (ml/min) 973±346
* 1015±365^ 1039±387 1131±390 <0.01 
Peak VO2 (ml/min/kg) 13.0±3.9 13.1±4.1 13.0±4.4 13.6±4.1 ns 
Peak VO2 (% of predicted) 52.1±16.4 52.3±16.7 52.2±16.1 52.9±16.2 ns 
VE/VCO2 slope 35.4±8.3 34.5±8.9 34.7±8.7 33.4±7.7 ns 
eGFR (ml/min/1.73m2) 64.9±23.1 66.2±23.5 68.3±22.4 67.4±21.2 ns 
Hb (g/dl) 13.3±1.8 13.3±1.7 13.6±1.7 13.5±1.8 ns 
NYHA (n,%)      
I 10 (5.5%) 23 (8.0%) 17 (8.5%) 10 (6.9%) ns 
II 89 (49.2%) 143 (50%) 110 (55.3%) 88 (61.1%)  
III 80 (44.2%) 112 (39.2%) 70 (35.2%) 45 (31.3%)  
IV 2 (1.1%) 8 (2.8%) 2 (1%) 1 (0.7%)  
HF Etiology (n,%)      
Idiopathic 58 (33%) 115 (40.4%) 85 (42.9%) 64 (44.4%) ns 
Ischemic 74 (42%) 117 (41.1%) 72 (36.4%) 57 (39.6%)  
Valvular 18 (10%) 28 (9.8%) 18 (9.1%) 6 (4.2%)  
Other 28 (16%) 25 (8.8%) 23 (11.6%) 17 (11.8%)  
ICD (n,%) 26 (14%)*;**,^^^,^ 84 (29%) 69 (35%) 65 (45%) <0.001 
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CRT (n,%) 11 (6%)* 31 (11%)* 30 (15%)^ 38 (26%) <0.001 
ACE-inhibitors (n,%) 127 (70.2%) 185 (64.5%) 129 (64.8%) 107 (74.3%) ns 
ARBs (n,%) 21 (11.6%)° 62 (21.7%) 53 (26.6%) 32 (22.2%) 0.003 
Diuretics (n,%) 153 (84.5%) 261 (91.3%) 179 (90.0%) 127 (88.2%) ns 
Statins (n,%) 36 (20.1%)*,**,@ 117 (40.9%) 88 (44.2%) 70 (48.6%) <0.001 
Allopurinol (n,%) 39 (21.8%)* 95 (33.2%) 65 (32.7%) 55 (38.2 %) 0.01 
MRAs (n,%) 86 (47.5%)*,^^ 170 (59.4%) 124 (62.3%) 99 (68.8%) <0.001 
Antiplatelets (n,%) 48 (26.5) 97 (33.9%) 52 (26.1%) 40 (27.8%) ns 
Oral anticoagulants (n,%) 140 (77.4%) 217 (75.9%) 155 (77.9%) 108 (75.0%) ns 
Digitalis (n,%) 86 (47.5%) 106 (37.1%) 69 (34.7%) 58 (40.3%) 0.056 
Amiodarone (n,%) 61 (33.7%) 87 (30.4%) 47 (23.6%) 41 (28.5%) 0.17 
 
BMI= body mass index; LVEF= Left ventricular ejection fraction; SBP= systolic blood pressure; HR= heart 
rate; Peak VO2= oxygen uptake at peak exercise; VE/VCO2 slope= minute ventilation/carbon dioxide 
production relationship (VE/VCO2) slope; eGFR= ; eGFR= Estimated Glomerular Filtration Rate by 
Modification of Diet in Renal Disease by Modification of Diet in Renal Disease; Hb= hemoglobin; HF= heart 
failure; NYHA= New York Heart Association; ICD= implantable cardioverter defibrillator; CRT= cardiac 
resynchronization therapy; ACE= angiotensin converting enzyme; ARB= angiotensin II receptor blockers; 
MRAs= mineralcorticoid receptor antagonists.* : <0.001 vs. high dose; ** : <0.001 vs. medium dose 
° : <0.01 vs. medium dose;   
^<0.05 vs. high dose; ^^: vs. medium dose ^^^: <0.05 vs. low dose 
@:<0.001 vs. low dose 
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Highlights 
 Usefulness of β-blockers in patients with atrial fibrillation and heart failure  
 No Impact of β1 selectivity on prognosis in heart failure patients with AF 
 Importance of daily β-blocker dose on long-term outcomes of patients with AF 
and HF 
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